HDAC抑制剂通过SOX10-IRF1轴诱导HLA I类分子在清细胞肉瘤细胞中
Minh Thi Nguyen1,2, Ryota Kikuchi1, Soshi Nishibu1
1Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama.
Biological & pharmaceutical bulletin
|November 20, 2024
概括
基斯脱乙酶 (HDAC) 抑制剂可以增强清细胞肉瘤 (CCS) 和黑色素瘤的免疫反应. 向HDAC1/3可以通过增加癌细胞免疫性来提高免疫疗法的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 清细胞肉瘤 (CCS) 是一种罕见的癌症,预后不佳.
- 免疫检查点抑制剂 (ICI) 在CCS中表现出有限的疗效.
- 之前的研究表明,组织激素脱乙酶 (HDAC) 抑制剂可以增强黑色素瘤的免疫性.
研究的目的:
- 调查HDAC抑制是否可以改善CCS中的ICI疗效.
- 探索SOX10-IRF1通路在CCS中HDAC介导免疫性中的作用.
- 确定潜在的新型治疗策略,用于CCS和黑色素瘤.
主要方法:
- 在CCS细胞中抑制HDAC.
- 通过小干扰RNA (siRNA) 的介导抑制SOX10.
- 推翻了IRF1.1. 这是一个非常好的方法.
- 对HLA类I和PD-L1表达的分析.
主要成果:
- 通过IRF1.1,HDAC抑制诱导了CCS细胞中的HLAI类表达.
- 抑制SOX10也导致HLAI类表达的增加.
- 特定抑制HDAC1/3上调的PD-L1表达与SOX10抑制相结合.
- 在IRF1中,降低了PD-L1的诱导作用.
结论:
- 抑制HDAC,特别是HDAC1/3,增加了CCS和黑色素瘤的免疫性.
- 这种机制涉及SOX10-IRF1通路和PD-L1上调.
- 在CCS和黑色素瘤中,HDAC抑制剂代表了与ICI结合治疗的潜在新策略.
更多相关视频
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
6.1K
09:11Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
6.5K
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
Inheritance of Chromatin Structures
6.2K
Epigenetics is the study of inherited changes in a cell's phenotype without changing the DNA sequences. It provides a form of memory for the differential gene expression pattern to maintain cell lineage, position-effect variegation, dosage compensation, and maintenance of chromatin structures such as telomeres and centromeres. For example, the structure and location of the centromere on chromosomes are epigenetically inherited. Its functionality is not dictated or ensured by the underlying...
6.2K
Hedgehog Signaling Pathway
7.3K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.3K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
